Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.

Antimicrobial agents and chemotherapy - 17 May 2022

Lai Ming-Tain, Feng Meizhen, Xu Min, Ngo Winnie, Diamond Tracy L, Hwang Carey, Grobler Jay A, Hazuda Daria J, Asante-Appiah Ernest

Abstract excerpt

Doravirine (DOR), a non-nucleoside reverse transcriptase inhibitor (NNRTI), was approved for treatment of HIV-1 infection in 2018. In the pivotal phase 3 trials, DRIVE-FORWARD and DRIVE-AHEAD, 7 out of 747 (0.9%) treatment-naive participants treated with DOR plus two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) met protocol-defined virologic failure criteria and showed phenotypic resistance to DOR at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Deoxyadenosines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Emtricitabine

Share to HIV Reverse Transcriptase

Share to Lamivudine

Share to Pyridones

Share to Reverse Transcriptase Inhibitors

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 35491829
DOI: 10.1128/aac.02223-21
PMCID: PMC9112941

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Doravirine and Islatravir Have Complementary Resistance Profiles and Create a Combination with a High Barrier to Resistance.PMID 35491829Read ↗

Islatravir Has a High Barrier to Resistance and Exhibits a Differentiated Resistance Profile from Approved Nucleoside Reverse Transcriptase Inhibitors (NRTIs).Semantic proximity Read ↗

Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir.Semantic proximity Read ↗

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infectionSemantic proximity Read ↗

Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials.Semantic proximity Read ↗

Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.Semantic proximity Read ↗

Kinetic Insights into the Enhanced Antiviral Activity of Islatravir against Doravirine Resistance-Associated Substitution Mutations in HIV-1 Reverse Transcriptase.Semantic proximity Read ↗

Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.Semantic proximity Read ↗

Combined doravirine and islatravir cooperate to inhibit NRTI and NNRTI resistant HIV-1 in vitro.Semantic proximity Read ↗

No antagonism or cross-resistance and a high barrier to the emergence of resistance in vitro for the combination of islatravir and lenacapavir.Semantic proximity Read ↗

Potential Role of Doravirine for the Treatment of Patients with Transmitted Drug ResistanceSemantic proximity Read ↗

Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.Semantic proximity Read ↗

Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.